The case for GLP-1 drugs like Ozempic possibly causing blindness is building. A new paper out this week describes several ...
A new study adds to a growing body of evidence that semaglutide has benefits other than weight loss or controlling diabetes.
Covering some 1.9million people in the UK, private health insurer Vitality has become the country’s first provider to offer customers discounted weight-loss treatments, such as Wegovy and Mounjaro.